Scilex Holding (SCLXW) Total Current Liabilities (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Total Current Liabilities of $501.8 million in Q1 2026, up 3.74% quarter-over-quarter from $483.7 million in Q4 2025, and up 81.96% on a YoY basis from $275.7 million in Q1 2025.
Scilex Holding (SCLXW) Total Current Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $501.8 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 81.96% year-over-year to $501.8 million; the TTM figure through Mar 2026 stood at $501.8 million (up 81.96% YoY), while the FY2025 annual figure was $483.7 million, up 86.28% from the prior year.
- Total Current Liabilities was $501.8 million for Q1 2026 at Scilex Holding, up from $483.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $501.8 million in Q1 2026 to a low of $41003.0 in Q1 2022.
- Historically, Total Current Liabilities has averaged $215.8 million across 5 years, with a median of $252.7 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities slumped 73.53% in 2022, then surged 157454.33% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $44.8 million in 2022, then jumped by 458.36% to $250.4 million in 2023, then climbed by 3.7% to $259.6 million in 2024, then soared by 86.28% to $483.7 million in 2025, then rose by 3.74% to $501.8 million in 2026.
- The last three Total Current Liabilities figures came in at $501.8 million (Q1 2026), $483.7 million (Q4 2025), and $358.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -30.24 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 501.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 501.75 Mn |
| Dec 31, 2025 | 483.65 Mn |
| Sep 30, 2025 | 358.95 Mn |
| Jun 30, 2025 | 305.93 Mn |
| Mar 31, 2025 | 275.74 Mn |
| Dec 31, 2024 | 259.64 Mn |
| Sep 30, 2024 | 281.54 Mn |
| Jun 30, 2024 | 255.45 Mn |
| Mar 31, 2024 | 252.73 Mn |
| Dec 31, 2023 | 250.38 Mn |
| Sep 30, 2023 | 228.58 Mn |
| Jun 30, 2023 | 103.58 Mn |
| Mar 31, 2023 | 64.60 Mn |
| Dec 31, 2022 | 44.84 Mn |
| Sep 30, 2022 | 809,292.00 |
| Jun 30, 2022 | 598,646.00 |
| Mar 31, 2022 | 41,003.00 |
| Dec 31, 2021 | 169.42 Mn |
| Sep 30, 2021 | 43,569.00 |
| Jun 30, 2021 | 20,025.00 |